Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management

NCT07821931 ↗

Phase 4 Not yet recruiting 58 enrolled Stanford University

RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to learn if a non-opioid pain medicine called suzetrigine can lower how much opioid pain medicine adults need after tonsil surgery (tonsillectomy) or a similar throat surgery.

Timeline

Start: 2026-11
Primary completion: 2027-06
Completion: 2027-07

Publications

Background Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870.
Background Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, Aertgeerts K, Negulescu PA, Lechner SM. Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain Ther. 2025 Apr;14(2):655-674. doi: 10.1007/s40122-024-00697-0. Epub 2025 Jan 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suzetrigine	Small molecule	50 mg	Oral
Background	Acetaminophen	Small molecule	1000 mg	—
Background	Oxycodone	Other / unclassified	5 mg	—
Background	Oxycodone	Other / unclassified	10 mg	—

Indications

No indication recorded.